Prostate Cancer

Prostate cancer is an epithelial malignant tumor that occurs in the prostate and is the most common tumor of the male genitourinary system. Prostate cancer is highly prevalent in elderly men, with 80% of cases occurring in men over 65 years of age. The global incidence of prostate cancer continues to rise, and there were nearly 1.3 million new cases and 359,000 deaths worldwide in 2018. The pathogenic factors of prostate cancer have not been fully elucidated, and may be related to age, race, genetics, environment, food, obesity, and sex hormones.

Diagnosis of Prostate Cancer

Prostate screening. Prostate-specific antigen (PSA) test combined with the digital rectal examination (DRE) helps to identify prostate cancer in the earliest stages.

• Digital rectal examination (DRE) examines the prostate for irregular nodules, tumor size, hardness, extension, etc. It can detect early prostate cancer.
• Prostate-specific antigen (PSA) test is performed by drawing blood for a PSA analysis. A small amount of PSA in the blood is normal. If the blood PSA is higher than the normal level, prostate infection, inflammation, enlargement or cancer may occur.

Confirmed prostate cancer. If the DRE or PSA test finds abnormalities, further examinations for prostate cancer are required.

• Rectal B-ultrasound can find cancer nodules, and the tumor is hypoechoic.
• Prostate biopsy is guided by rectal B-ultrasound biopsy and pathological examination to determine the presence of cancer cells.

Prostate cancer grade judgment

• Gleason score. When confirming the presence of cancer, the grade of cancer cells should be determined by the Gleason score. The higher the grade, the more aggressive the disease and the faster the spread. If cancer shows signs of spread, one or more imaging tests, such as bone scan, CT and MRI, etc., should also be performed to determine the extent of cancer spread.

Advantages of Our Products

Creative Biogene's prostate cancer diagnostic products are often used in prostate screening. Most of them are one-step serum, plasma or whole blood PSA test kits. Their analysis modes include enzyme immunoassay, chemiluminescent immunoassay and rapid molecular determination, etc., have the following advantages:

• High sensitivity, specificity and reproducibility.
• Stable and reliable performance.
• Standardized packaging.
• Ready-to-use reagents to shorten the initial preparation time.
• Room temperature testing.
• Short detection time.
• Provide all necessary reagents.

Creative Biogene is an expert in the field of prostate cancer diagnosis. More discounts, more surprises, we look forward to your selection! We will provide you with our optimal products.

Please contact us for more details.

Reference

1. Ilic D, et al. (2018). "Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis." Bmj. 362: k3519.